APA (7th ed.) Citation

Albahdal, A. S., Alotaibi, A. M., Alanazi, M. A., Abanmy, N., Alwhaibi, M., & AlRuthia, Y. (2024, February). Cost-consequence analysis of tocilizumab versus adalimumab and etanercept among rheumatoid arthritis patients in Saudi Arabia: A single-center study. Cost Effectiveness and Resource Allocation.

Chicago Style (17th ed.) Citation

Albahdal, Areej S., Amjad M. Alotaibi, Miteb A. Alanazi, Norah Abanmy, Monira Alwhaibi, and Yazed AlRuthia. "Cost-consequence Analysis of Tocilizumab Versus Adalimumab and Etanercept Among Rheumatoid Arthritis Patients in Saudi Arabia: A Single-center Study." Cost Effectiveness and Resource Allocation Feb. 2024.

MLA (9th ed.) Citation

Albahdal, Areej S., et al. "Cost-consequence Analysis of Tocilizumab Versus Adalimumab and Etanercept Among Rheumatoid Arthritis Patients in Saudi Arabia: A Single-center Study." Cost Effectiveness and Resource Allocation, Feb. 2024.